JNJ-87704916
Phase 1Small molecule
JNJ-87704916 is one of 31 small molecule programs targeting Neoplasms. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
45 competitors in Neoplasms
#DrugCompanyPhaseTrials
1Xtandi
AstellasPhase 3
Tecentriq
RochePhase 3
Avastin
RochePhase 3
Taxol
TevaPhase 3
Alimta
SShawn Eagle
Phase 3
Alimta
EEagle Pharmaceuticals, Inc.
Phase 3
Fludara
SanofiPhase 2
Cyramza
Eli LillyPhase 2
Gemzar
Johnson & JohnsonPhase 2
Verzenio
Eli LillyPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Neoplasms1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JNJ-87704916. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details